Hospira company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

hospira.com

Founded Year

2004

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Hospira

Hospira is a provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness by improving patient and caregiver safety while reducing healthcare costs.

Hospira Headquarter Location

275 N Field Dr

Lake Forest, Illinois, 60045,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Hospira

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hospira is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Hospira Patents

Hospira has filed 135 patents.

The 3 most popular patent topics include:

  • Beta blockers
  • Sedatives
  • Anesthesia
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/17/2015

5/31/2022

Diabetes, Dosage forms, Drug delivery devices, Insulin therapies, Pumps

Grant

Application Date

12/17/2015

Grant Date

5/31/2022

Title

Related Topics

Diabetes, Dosage forms, Drug delivery devices, Insulin therapies, Pumps

Status

Grant

Latest Hospira News

Risks for CKD, heart failure higher for Black vs. white adults with type 2 diabetes

Jun 29, 2022

Disclosures: Paul reports being an employee of AstraZeneca; serving as a consultant or speaker for Amylin Pharmaceuticals, AstraZeneca, GI Dynamics, Guangzhou Zhongyi Pharmaceutical, Novartis, Roche and Sanofi Aventis; and receiving grants in support of investigator and investigator-initiated clinical studies from Amylin Pharmaceuticals, AstraZeneca, Hospira, Merck, Novo Nordisk, Pfizer and Sanofi. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Black adults with type 2 diabetes have a higher risk for developing chronic kidney disease and heart failure than white adults, and the time from diabetes diagnosis to CKD or heart failure was 12 years or less in all age groups. In findings published in Diabetes Care from more than 1.5 million U.S. residents with type 2 diabetes, risks for developing CKD and heart failure varied by ethnicity, age group and sex. Additionally, most age groups with type 2 diabetes developed CKD and heart failure within a decade of type 2 diabetes diagnosis, and CKD had a greater mediation effect on the risk difference in heart failure compared with the mediation effects of heart failure on CKD risk differences between Black and white adults. Black adults with type 2 diabetes aged 18 to 59 years have a higher risk for heart failure than white adults. Data were derived from Paul SK, et al. Diabetes Care. 2022;doi:10.2337/dc21-2349. “We believe that the large cohort size, robust study design, use of advanced data mining methods, and appropriate assessment of confounders ensure reliable population-level estimates and reflect real-world patterns of CKD and heart failure risk in people with incident type 2 diabetes in a detailed evaluation by age, ethnicity and sex,” Sanjoy K. Paul, PhD, professor of clinical epidemiology and biostatistics at Melbourne EpiCentre, University of Melbourne and Melbourne Health, Australia, and colleagues wrote. “Our findings relative to different risk paradigms in African Americans and white Americans, including a mediation effect difference of heart failure and CKD, reflect the inherent differences in how the pathway of development of cardiometabolic diseases differ in these ethnic groups.” Researchers analyzed deidentified patient-level data from the Centricity electronic medical record database. White adults (n = 1,491,672) and Black adults (n = 311,333) aged 18 to 70 years diagnosed with type 2 diabetes from 2000 to September 2018 were included. Participants were stratified into four groups based on age at type 2 diabetes onset: 18 to 39 years, 40 to 49 years, 50 to 59 years and 60 to 70 years. The presence of CKD and heart failure were confirmed through relevant disease identification codes. Researchers assessed the risks, mediation effects and time to diagnosis of CKD and heart failure for both Black and white adults as well as for each age group. Higher risks for Black adults The risk for developing CKD among adults with type 2 diabetes was higher for Black adults compared with white adults aged 18 to 39 years (HR = 1.21; 95% CI, 1.17-1.26), 40 to 49 years (HR = 1.25; 95% CI, 1.22-1.28), 50 to 59 years (HR = 1.21; 95% CI, 1.19-1.24) and 60 to 70 years (HR = 1.1; 95% CI, 1.08-1.12). Black adults with type 2 diabetes also had a higher risk for heart failure than white adults aged 18 to 39 years (HR = 2.21; 95% CI, 1.98-2.45), 40 to 49 years (HR = 1.86; 95% CI, 1.75-1.97) and 50 to 59 years (HR = 1.54; 95% CI, 1.48-1.6). No significant difference in heart failure risk was found for adults aged 60 to 70 years. After stratifying further by sex, Black men aged 18 to 59 years had an 11% to 49% higher risk for developing CKD than women. White men aged 18 to 39 years had a 23% higher risk for CKD than women, whereas white men aged 50 years and older had a 7% to 14% lower CKD risk than women (P < .01 for all). Time to CKD, heart failure less than 10 years for most The mean time from diabetes diagnosis to first CKD event was between 5.1 and 9.7 years across all age groups in Black and white adults with type 2 diabetes. The time from diabetes diagnosis to CKD was 3.6 years longer for Black adults aged 18 to 39 years compared with those aged 60 to 70 years. White adults aged 18 to 39 years had a time to CKD event 4 years longer than those aged 60 to 70 years. The mean time from diabetes diagnosis to a heart failure event was between 6.9 and 12.1 years across all age groups. The time to a heart failure event was 3.4 years longer in Black adults aged 18 to 39 years compared with those aged 60 to 70 years, and 4.1 years longer in white adults aged 18 to 39 years compared with those aged 60 to 70 years. The overall independent mediation effect of CKD in the context of risk difference in heart failure between Black adults and white adults was 54% in the 18-to-39-year age group, 40% in the 40-to-49-year age group, 41% in the 50-to-59-year age group and 91% in the 60-to-70-year age group. The mediation effect of heart failure in the context of risk difference in CKD between the two ethnicities was 13% in adults aged 18 to 39 years, 39% in those aged 40 to 49 years, 35% in adults aged 50 to 59 years and 15% in those aged 60 to 70 years. “Both CKD and heart failure were apparent in some individuals within a few years of a type 2 diabetes diagnosis, even among those diagnosed at age < 40 years and particularly within the African American population,” the researchers wrote. “An urgent need exists to incorporate multidisciplinary care in the identification of high-risk patients from type 2 diabetes onset, along with legislative support promoting equitable access to therapies and care, especially for young, vulnerable and underrepresented patient populations.” Read more about

  • When was Hospira founded?

    Hospira was founded in 2004.

  • Where is Hospira's headquarters?

    Hospira's headquarters is located at 275 N Field Dr, Lake Forest.

  • What is Hospira's latest funding round?

    Hospira's latest funding round is Acq - P2P.

  • Who are the investors of Hospira?

    Investors of Hospira include Pfizer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.